MedTrace Logo

Aflibercept and Bevacizumab for Diabetic Maculopathies

NCT06850571 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2025-09-19

No results posted yet for this study

Summary

The goal of this clinical trial is to to evaluate the clinical outcomes following treatment with bevacizumab versus aflibercept. These outcomes include:

* Functional changes: The visual outcomes achieved by testing visual acuity
* Anatomical changes: macular thickness and edema by optical coherence tomography (OCT).

Conditions

  • Diabetic Maculopathy

Interventions

DRUG

Bevacizumab Injection [Avastin]

1.25 mg intravitreal injection given once monthly for three consecutive months.

DRUG

Aflibercept 2Mg/0.05Ml Inj,Oph

2.0 mg intravitreal injection given once monthly for three consecutive months.

Sponsors & Collaborators

  • Baghdad Medical City

    collaborator OTHER

  • Al-Mustansiriyah University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-20
Primary Completion
2025-12-01
Completion
2025-12-01

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06850571 on ClinicalTrials.gov